Analyzing C4 Therapeutics (CCCC) & Its Peers

C4 Therapeutics (NASDAQ:CCCC) is one of 846 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare C4 Therapeutics to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Institutional and Insider Ownership

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares C4 Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
C4 Therapeutics	$35.95 million	-$104.99 million	-4.17
C4 Therapeutics Competitors	$729.47 million	$11.46 million	-14.85

C4 Therapeutics’ peers have higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings for C4 Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	1	5	0	2.57
C4 Therapeutics Competitors	9905	15274	45603	1595	2.54

C4 Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. As a group, “Biotechnology” companies have a potential upside of 99.37%. Given C4 Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe C4 Therapeutics is more favorable than its peers.

Profitability

This table compares C4 Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-282.22%	-37.71%	-26.42%
C4 Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Risk and Volatility

C4 Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500. Comparatively, C4 Therapeutics’ peers have a beta of 1.15, indicating that their average share price is 15% more volatile than the S&P 500.

Summary

C4 Therapeutics beats its peers on 9 of the 13 factors compared.

About C4 Therapeutics

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity. C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.